The study focused on tumor-associated macrophages, or TAMs, which are among the most abundant immune cells in the pancreatic tumor microenvironment. Macrophages are remarkably plastic cells: depending on the signals they receive, they can polarize toward an M1-like state, which produces inflammatory signals such as tumor necrosis factor-alpha, interleukin-6, interleukin-1 beta, and inducible nitric oxide synthase, and which supports the activation of cytotoxic T cells. Alternatively, they can drift toward an M2-like state, which suppresses immune responses, promotes tissue remodeling, and helps tumors evade destruction. In pancreatic cancer, the balance is heavily tilted toward the immunosuppressive M2-like phenotype, contributing to the tumors’ well-deserved reputation as immunological fortresses that checkpoint inhibitors alone rarely penetrate.

High-dose vitamin C has attracted growing scientific interest over the past decade. Unlike the modest dietary amounts obtained from fruit and vegetables, pharmacological doses of ascorbate, typically delivered intravenously, achieve blood concentrations far above what oral supplementation can reach. At these levels, vitamin C can act as a pro-oxidant in the tumor microenvironment, generating hydrogen peroxide and imposing metabolic stress on cancer cells, while also exerting immunomodulatory effects on various immune cell populations. Previous work has hinted at antitumor activity in several cancer models, but whether the molecule could reshape the macrophage landscape of pancreatic tumors, and what signaling pathways might be responsible, remained unclear.

To address these questions, the researchers evaluated high-dose vitamin C in a subcutaneous KPC mouse model, a widely used preclinical system that recapitulates key features of pancreatic ductal adenocarcinoma. The results were striking: treatment with high-dose vitamin C significantly inhibited pancreatic tumor growth and prolonged survival in the animals. This established that the intervention had genuine antitumor activity in vivo, but the more important question was how it achieved that effect, and whether the immune system was involved.

To dissect the mechanism, the team turned to in vitro models using mouse and human macrophages stimulated with lipopolysaccharide and interferon-gamma, a combination that reliably drives macrophages toward the M1 phenotype. When vitamin C was added to this stimulation, it markedly enhanced M1 polarization, boosting the expression of classic M1 markers and inflammatory mediators. Crucially, the treatment did not markedly increase M2-associated features, meaning the effect was a genuine push toward the anti-tumor state rather than a nonspecific perturbation of macrophage biology. The finding was consistent across both mouse bone marrow-derived macrophages and human macrophage models, suggesting the phenomenon is not a species-specific quirk.

The molecular machinery behind this effect was probed with a battery of complementary techniques, including RNA sequencing, western blotting, flow cytometry, pharmacological inhibition, and siRNA-mediated knockdown. These experiments converged on the JAK2-STAT1 signaling pathway, a canonical inflammatory axis through which interferon-gamma exerts many of its effects on macrophages. Vitamin C treatment increased the phosphorylation, and therefore the activation, of both JAK2 and STAT1. When the researchers blocked this pathway, either with pharmacological inhibitors or by silencing JAK2 with siRNA, the ability of vitamin C to enhance M1 polarization was substantially diminished. This places JAK2-STAT1 activation at the center of the mechanism, positioning vitamin C as an amplifier of the very interferon-driven signals that define pro-inflammatory macrophage identity.

Perhaps the most persuasive piece of evidence came from the macrophage depletion experiments. When the researchers depleted macrophages in vivo using clodronate liposomes, a standard technique in which lipid vesicles containing the toxic drug clodronate are engulfed and destroy macrophages, the antitumor efficacy of high-dose vitamin C was markedly attenuated. In other words, without macrophages present, vitamin C largely lost its ability to fight the tumors. This experiment provides strong causal support for the idea that the benefit of vitamin C in this setting depends on macrophage-centered immune modulation, rather than on direct tumor cell killing alone, even though direct cytotoxic mechanisms of pharmacological ascorbate are well documented in other contexts.

The study then moved to the clinically most consequential question: whether vitamin C could improve the performance of immune checkpoint inhibitors in pancreatic cancer. Anti-PD-1 antibodies, which unleash T cells by blocking the programmed cell death protein 1 brake on their surface, have produced disappointing results in pancreatic cancer as monotherapy, in large part because the tumor microenvironment lacks the pre-existing T cell activity that PD-1 blockade requires. In the KPC model, combining high-dose vitamin C with anti-PD-1 therapy enhanced treatment efficacy compared with either approach alone. The combination was accompanied by increased numbers of M1-like macrophages and greater infiltration of CD8-positive cytotoxic T cells into the tumor microenvironment, painting a picture in which vitamin C-conditioned macrophages help create the inflammatory context that allows checkpoint blockade to recruit and activate tumor-killing T cells.

The implications of this work extend beyond pancreatic cancer, although the disease remains the most urgent beneficiary. Pancreatic ductal adenocarcinoma is projected to become one of the leading causes of cancer death in the coming decades, and the near-total failure of immunotherapy in this tumor type has made combination strategies a central research priority. The study offers a mechanistically grounded rationale for pairing pharmacological vitamin C with checkpoint inhibitors, a combination that is comparatively inexpensive and has a well-characterized safety profile at appropriate doses. It also adds to a broader shift in oncology research: rather than targeting tumor cells exclusively, many of the most promising new strategies aim to reprogram the stromal and immune cells that tumors co-opt for their own protection.

At the same time, the researchers and the field at large are careful to note the distance between mouse models and human patients. The findings come from subcutaneous KPC models and in vitro macrophage systems, and the authors themselves frame the work as providing a rationale for further investigation rather than an established treatment strategy. Clinical trials will be needed to determine whether the macrophage-reprogramming effects observed in mice translate to human pancreatic tumors, what dosing regimens are optimal, and how vitamin C-based combinations should be sequenced with existing chemotherapy and immunotherapy. Still, for a disease with so few options and such a desperate need for new ideas, the demonstration that a simple vitamin can flip macrophages from tumor allies into tumor attackers, through a defined JAK2-STAT1 mechanism, and thereby unlock the potential of PD-1 blockade, is the kind of result that could reshape how the field thinks about the immunosuppressive tumor microenvironment. The study, published open access on 13 October 2026, was supported by funding from the National Key Technologies R&D Program, the National Natural Science Foundation of China, and other Chinese research programs, and was conducted under protocols approved by the institutional animal care committee of Beijing Friendship Hospital.

Subject of Research: High-dose vitamin C modulation of tumor-associated macrophage polarization and anti-PD-1 immunotherapy efficacy in pancreatic cancer

Article Title: High-dose vitamin C augments LPS/IFN-γ-induced M1 macrophage polarization through JAK2-STAT1 activation and promotes anti-PD-1 efficacy in pancreatic cancer

Article References: Zhao, H., Fu, W., Zhang, W., Li, X., Zhang, T., Yao, H., & Zhang, Z. (2026). High-dose vitamin C augments LPS/IFN-γ-induced M1 macrophage polarization through JAK2-STAT1 activation and promotes anti-PD-1 efficacy in pancreatic cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04592-9

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04592-9

Keywords: pancreatic cancer, high-dose vitamin C, tumor-associated macrophages, M1 macrophage polarization, JAK2-STAT1 pathway, anti-PD-1 therapy, immune checkpoint inhibitors, tumor microenvironment, CD8-positive T cells, cancer immunotherapy, KPC mouse model, immunomodulation

HER2, a transmembrane receptor tyrosine kinase belonging to the EGFR family, is best known as a driver of breast and gastric cancers, but it is also overexpressed in roughly 7.7 to 23 percent of NSCLC patients. These tumors tend to be aggressive and respond poorly to chemotherapy and conventional targeted agents. Antibody-drug conjugates such as trastuzumab deruxtecan have shown promise, yet they are currently recommended only for HER2-mutant disease, and the DESTINY-Lung01 trial documented substantial grade 3 or higher toxicity and treatment-related deaths in HER2-overexpressing patients. The research team, led by investigators affiliated with Hebei Medical University, set out to fill this gap with a vaccine strategy that recruits the patient’s own immune system rather than relying on systemic drug exposure.

The vaccine itself is a classic product of the post-COVID mRNA era. The researchers synthesized mRNA encoding the human HER2 extracellular domain through in vitro transcription, capping, and polyadenylation, then encapsulated it in lipid nanoparticles built on the well-characterized MC3 ionizable lipid formulation, mixed at a molar ratio of DLin-MC3-DMA, DSPC, cholesterol, and DMG-PEG2000 of 50:10:38.5:1.5. Using a microfluidic device, they produced particles with a median diameter of about 71 nanometers, a polydispersity index of just 0.072, and an encapsulation efficiency of roughly 80 percent. Cryo-electron microscopy showed uniform, spherical particles with dense mRNA cores. Once injected intramuscularly, the nanoparticles deliver their cargo to dendritic cells and other host cells, where the HER2 protein is translated, processed by the proteasome, and presented on both MHC class I and class II molecules, priming cytotoxic T cells and antibody production against what is normally a self-antigen.

Immunogenicity was robust. In both BALB/c and C57BL/6 mice, three doses of the vaccine drove high serum titers of HER2-specific antibodies, and booster immunization pushed titers progressively higher over time. Crucially, the antibody response worked across two different MHC backgrounds, hinting that the antigen design may generalize beyond a single genetic context. Safety testing at the day 70 endpoint showed no pathological changes in heart, liver, lung, or spleen on histology, and complete blood counts, liver enzymes, renal markers, and cardiac enzymes all remained within normal ranges. The only notable finding was reduced spleen weight in vaccinated mice, which the authors attribute to relief of tumor-driven compensatory splenic enlargement rather than toxicity.

To test efficacy, the team engineered a Lewis lung carcinoma cell line stably overexpressing human HER2 using a transposon system, confirming expression levels that fell between the HER2-high breast cancer line SKBR3 and the moderate expresser A549, mirroring the clinical spectrum seen in NSCLC patients. In a prophylactic setting, mice vaccinated before tumor challenge showed significantly slower tumor growth from day 4 onward, and the addition of radiotherapy, delivered as three 8-Gy fractions totaling 24 Gy from a clinical linear accelerator, produced the smallest tumors of any group throughout the 24-day observation window. A striking inverse correlation emerged between antibody titer and final tumor volume, with a Pearson coefficient of -0.889, suggesting the humoral response tracks closely with tumor control.

The therapeutic arm of the study was arguably more clinically relevant. When vaccination began only after tumors were established, with radiotherapy administered on day 14, the combination again outperformed either modality alone, with significantly smaller tumor volumes from day 3 onward and the greatest reductions in both tumor weight and proliferative Ki67 staining. Splenic T lymphocytes from combination-treated mice showed the highest cytotoxic killing of HER2-LLC cells in co-culture assays. Immunohistochemistry confirmed that both HER2 expression and proliferation markers dropped most steeply in the combination group, consistent with the vaccine sensitizing tumors to radiation.

Flow cytometry revealed the mechanistic story underneath these outcomes. Within tumors, the combination therapy increased CD8-positive T cell infiltration beyond either monotherapy and raised the CD8-to-CD4 ratio significantly. Macrophages shifted decisively toward the antitumor M1 phenotype: the M1-to-M2 ratio rose twentyfold with the vaccine alone and thirtyfold with the combination, indicating that radiation amplifies a vaccine-driven reprogramming of the myeloid compartment. NK cells and B cells also expanded, while immunosuppressive regulatory T cells declined. In the spleen, the same pattern held, accompanied by elevated secretion of IFN-gamma, TNF-alpha, IL-2, and IL-4, painting a picture of coordinated systemic Th1-dominant activation with humoral support.

One of the most intriguing findings concerns T cell differentiation. The combination regimen reduced the fraction of CD44-negative CD62L-negative double-negative T cells, a short-lived terminally differentiated subset, while boosting CD8-positive effector memory cells and granzyme B-expressing cytotoxic cells. The authors interpret this as radiation-induced bystander activation at work: irradiated tumor cells undergo immunogenic cell death, releasing damage-associated molecular patterns that redirect quiescent T cells away from transient effector fates and toward durable, memory-like phenotypes with sustained killing capacity. If this holds in humans, the combination might not only shrink existing tumors but seed long-term immune memory against recurrence.

The authors are candid about the limitations of their model. Human HER2 is a xenogeneic antigen in mice, lacking a normal-tissue homolog, which likely inflates the apparent immunogenicity and prevents meaningful assessment of autoimmune risk, a critical concern for any self-antigen-targeted vaccine. The engineered cell line cannot reproduce the heterogeneity of HER2 expression in human tumors, all experiments used male mice to avoid hormonal confounders, and safety was assessed only at a single terminal time point. The team proposes follow-up work in HER2-transgenic or humanized models, dynamic toxicity monitoring, T cell depletion and antibody transfer experiments, epitope mapping, and combination studies with immune checkpoint inhibitors.

Even with those caveats, the study stakes out an important translational position. Only a handful of LNP-based mRNA vaccines have reached clinical testing in lung cancer, and none have specifically targeted HER2-overexpressing patients. Earlier mRNA approaches, such as the five-antigen vaccine BI 1361849 combined with radiotherapy in stage IV NSCLC, demonstrated tolerability and immune activation but did not focus on this molecular subtype. By showing that a single-antigen HER2 mRNA-LNP vaccine can both prevent tumor establishment and radiosensitize established disease, the researchers provide a preclinical rationale for a radio-immunotherapy strategy aimed at one of the most refractory corners of lung oncology, where the flexibility of the mRNA platform could eventually support personalized antigen selection and rapid clinical iteration.

Subject of Research: Combined HER2-targeted mRNA-LNP vaccine and radiotherapy immunotherapy for HER2-overexpressing non-small cell lung cancer in mice

Article Title: Combined HER2‐targeted mRNA‐LNP vaccine and radiotherapy suppress Lewis lung carcinoma growth in mice: Efficacy and mechanistic insights

Article References: Wang, S., Jing, S., Zou, S., Zhang, Y., Ge, M., Gao, K., Li, X., Zhao, L., & Wang, J. (2026). Combined HER2 ‐targeted mRNA ‐ LNP vaccine and radiotherapy suppress Lewis lung carcinoma growth in mice: Efficacy and mechanistic insights. Bioengineering & Translational Medicine, 11(5), Article e70160. https://doi.org/10.1002/btm2.70160

Image Credits: AI Generated

DOI: 10.1002/btm2.70160

Keywords: mRNA vaccine, lipid nanoparticles, HER2, non-small cell lung cancer, radiotherapy, radio-immunotherapy, CD8 T cells, M1 macrophage polarization, tumor microenvironment, Lewis lung carcinoma, immunogenic cell death, preclinical study